Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable?

Basit Öğe Kaydı
dc.authoridAkgun, Metin/0000-0003-3404-4274
dc.authoridMeral, Mehmet/0000-0003-4476-9922
dc.contributor.authorGunen, Hakan
dc.contributor.authorMirici, Arzu
dc.contributor.authorMeral, Mehmet
dc.contributor.authorAkgun, Metin
dc.date.accessioned2025-01-27T20:54:14Z
dc.date.available2025-01-27T20:54:14Z
dc.date.issued2009
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose of review Systemic corticosteroids are strongly recommended in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD). As COPD patients are usually elderly and are relatively immobile, side effects of systemic corticosteroids frequently outweigh their beneficial effects. On the contrary, nebulized corticosteroid solutions have a negligible systemic side-effect profile. In this review, as an alternative to systemic corticosteroids, the place of nebulized corticosteroids in exacerbation periods of COPD was summarized. Recent findings The number of trials in the literature is increasing. Regarding the available data, high dose nebulized budesonide was found as effective as systemic corticosteroids in exacerbations of COPD. The side-effect profile, blood glucose level in particular, is better for nebulized budesonide. Summary Findings from recent studies are giving a positive impression on the role of high dose nebulized budesonide in exacerbations of COPD. However, larger and statistically high powered trials testing different types of nebulized corticosteroid solutions with varying dosages are still lacking. Before recommending the routine use of nebulized corticosteroids in exacerbations, present findings need to be confirmed with further studies of high quality.
dc.identifier.doi10.1097/MCP.0b013e32832185da
dc.identifier.endpage137
dc.identifier.issn1070-5287
dc.identifier.issue2
dc.identifier.pmid19532028
dc.identifier.scopus2-s2.0-62349085566
dc.identifier.scopusqualityQ2
dc.identifier.startpage133
dc.identifier.urihttps://doi.org/10.1097/MCP.0b013e32832185da
dc.identifier.urihttps://hdl.handle.net/20.500.12428/26017
dc.identifier.volume15
dc.identifier.wosWOS:000264280700009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofCurrent Opinion in Pulmonary Medicine
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectefficacy of nebulized corticosteroids
dc.subjectexacerbations of chronic obstructive pulmonary disease
dc.subjectnebulized budesonide
dc.subjectnebulized corticosteroids
dc.subjectside effects of nebulized corticosteroids
dc.titleSteroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu